Expression of oncogenic Ras in 23A2 skeletal myoblasts is sucient to induce both a transformed phenotype and a dierentiation-defective phenotype, but the signaling pathways activated by oncogenic Ras in these cells and their respective contribution to each phenotype have not been explored. In this study, we investigated MAP kinase activity in control 23A2 myoblasts and in 23A2 myoblasts rendered dierentiation-defective by the stable expression of an oncogenic (G12V)Ha-ras gene (Ras9 cells). The MAP kinase immunoprecipitated from Ras9 cells was 30 ± 40% more active than that from control 23A2 cells. To establish if this elevated MAP kinase activity is essential to the maintenance of the oncogenic Ras-induced phenotype, we utilized the selective MAP kinase kinase 1 (MEK1) inhibitor, PD 098059. PD 098059 decreased the MAP kinase activity in Ras9 cells to the level found in 23A2 cells. PD 098059 did not aect the ability of 23A2 myoblasts to dierentiate. PD 098059 reverted the transformed morphology of Ras9 cells but did not restore the ability of these cells to express the muscle-speci®c myosin heavy chain gene or to form muscle ®bers. Treatment with PD 098059 also did not aect the ability of oncogenic Ha-Ras to establish a non-myogenic phenotype in C3H10T1/2 cells co-expressing MyoD. These results demonstrate that the activation of MAP kinase is necessary for the transformed morphology of Ras9 cells but is not required by oncogenic Ras to establish or to maintain a dierentiation-defective phenotype. While these data do not rule out the possibility that constitutive signaling by MEK1 or MAP kinase could inhibit myoblast dierentiation, they clearly demonstrate that other pathways activated by oncogenic Ras are sucient to inhibit dierentiation.
Introduction
The mammalian ras family consists of three genes, Ha-, K-and N-, which encode 21 Kd proteins localized to the cytoplasmic side of the plasma membrane (Lowy and Willumsen, 1993) . Activation of Ras is accomplished by the stimulated exchange of GDP for GTP in response to a series of well-characterized events initiated by external agonists (Feig, 1993; Burgering and Bos, 1995) . Ras is returned to its inactive, GDPbound state by GAP-or Neuro®bromin-mediated stimulation of its intrinsic GPTase activity (Hall, 1990; McCormick, 1995) . Mutated versions of Ras which are oncogenic are insensitive to regulation by GAP and Neuro®bromin (Lowy and Willumsen, 1993) . Ras signaling plays a central role in a multitude of biological responses including the transformation of ®broblasts, the dierentiation of PC12 cells , and the migration of endothelial cells (Fox et al., 1994) . Skeletal myoblasts provide an intriguing system in which to dissect Ras signaling since expression of oncogenic Ras in these cells results in both transformation and the inhibition of differentiation (Konieczny et al., 1989) . While the signaling events utilized by oncogenic Ras in ®broblasts and PC12 cells have been well characterized (Cowley et al., 1994; Dudley et al., 1995; White et al., 1995; Joneson et al., 1996) , whether the same or distinct signaling pathways are utilized by oncogenic Ras to transform myoblasts and to abrogate their dierentiation has not been explored.
The in vitro dierentiation of committed skeletal myoblasts is a complex process composed of temporally separable events (Andres and Walsh, 1996) . Proliferating myoblasts must irreversibly exit the cell cycle at a speci®c point, express a battery of musclespeci®c genes and fuse to form multinucleate myotubes (Rudnicki and Jaenisch, 1995) . Dierentiation is positively mediated by the activation of the muscle regulatory factor (MRF) family which is composed of MyoD, myogenin, Myf5 and MRF4 (Ludolph and Konieczny, 1995; Rudnicki and Jaenisch, 1995) . These basic helix ± loop ± helix transcription factors bind DNA and activate the gene expressing the cell cycle inhibitor, Waf-1 (Guo et al., 1995; Halevy et al., 1995; Parker et al., 1995) , as well as the genes expressing skeletal muscle proteins such as myosin heavy chain (MHC) (Ludolph and Konieczny, 1995; Rudnicki and Jaenisch, 1995) . Although the molecular mechanisms controlling myoblast dierentiation are well characterized at the transcriptional level, the signaling molecules responsible for transmitting environmental stimuli across the plasma membrane through the cytoplasm to the MRFs have not been identi®ed.
Understanding the signaling events controlling the induction of myoblast dierentiation has relied almost exclusively on information gained from studying signaling molecules which inhibit dierentiation. Myoblast dierentiation is inhibited by culturing myoblasts in fetal serum, FGF2, TGFb1 or by the expression of proteins encoded by a number of viral and cellular oncogenes including the tyrosine kinase Src, the Ras GTPase and the transcription factors Myc, Fos and Jun (Florini et al., 1991; Schneider and Olson, 1988; Olson, 1992; Alema and Tato, 1994) . The inhibition of dierentiation by FGF2, TGFb1 or Ras does not rely on their mitogenic properties (Lathrop et al., 1985a,b; Florini et al., 1986; Massague et al., 1986; Olson et al., 1986 Olson et al., , 1987 Spizz et al., 1986; Clegg et al., 1987; Payne et al., 1987; Gossett et al., 1988; Konieczny et al., 1989; Vaidya et al., 1989a) . Furthermore, the dierentiation-defective phenotype established by these molecules is reversible, implying that the signaling pathways activated by each must be continuously stimulated to maintain the eect (Lathrop et al., 1985b; Olson et al., 1986; Clegg et al., 1987; Gossett et al., 1988; Vaidya et al., 1989b; . The Ras oncogene, because of its pivotal role in proliferation, transformation and the differentiation of other tissue types (Lowy and Willumsen, 1993) , is perhaps the most interesting of these myogenic inhibitors.
Activation of Ras is followed by the activation of Raf-1/B-Raf, MAP kinase kinase 1 (MEK1), and members of the MAP kinase family Moodie et al., 1994; Jaiswal et al., 1994; Jelinek et al., 1994; Reuter et al., 1995) . The signi®cance of this signaling pathway to the transformation of ®broblasts and the dierentiation of PC12 cells is well established (Cowley et al., 1994; Pang et al., 1995; Joneson et al., 1996) . However, the contribution of MAP kinase activation to the establishment or maintenance of the oncogenic Ras-induced transformation and inhibition of dierentiation in skeletal myoblasts has not been examined. In this study, we show that 23A2 myoblasts rendered transformed and dierentiation-defective by expression of oncogenic Ras (Ras9 cells) have increased MAP kinase activity when compared to 23A2 control myoblasts. We use PD 098059 (Alessi et al., 1995; Dudley et al., 1995; , a highly selective chemical inhibitor of MEK1 activation, to show that activation of MAP kinase is necessary for the serum-independent proliferation and morphological transformation of Ras9 cells, but is not required by oncogenic Ras to establish or maintain a block to myoblast dierentiation.
Results
MAP kinase activity in 23A2 myoblasts and 23A2 myoblasts expressing an oncogenic Ha-Ras protein 23A2 myoblasts can be induced to dierentiate both biochemically, as de®ned by the expression of musclespeci®c genes, and morphologically, as de®ned by the fusion of single cells into multinucleate myo®bers (Konieczny and Emerson, 1984) . The expression of an oncogenic Ha-ras gene in 23A2 myoblasts renders these cells transformed and dierentiation-defective (Konieczny et al., 1989) . To assess the signaling pathways activated by oncogenic Ras in 23A2 myoblasts, the MAP kinase activity in a 23A2 cell line stably expressing an oncogenic Ha-Ras protein (Ras9 cells) was compared to the MAP kinase activity in control 23A2 myoblasts. MAP kinase immunoprecipitated from Ras9 cells in growth medium (GM: BME plus 10% FBS) was 30 ± 40% more active than MAP kinase immunoprecipitated from the same number of 23A2 myoblasts in growth medium (Figure 1 ). This increase does not result from dierences in the total MAP kinase immunoprecipitated or from dierences in the total cellular amount of MAP kinase protein present in each extract (data not shown). To determine the extent to which MAP kinase activity decreases when cells are treated with differentiation medium (DM: BME plus 0% serum), MAP kinase was immunoprecipitated from equal numbers of 23A2 and Ras9 cells after 15, 30 and 60 min in dierentiation medium. By 60 min, the MAP kinase activity in both cell lines had decreased to roughly 50% of that found in each respective cell line maintained in growth medium (Figure 1) . No further decrease in MAP kinase activity was observed, even after 3 or 18 h in dierentiation medium (CMW and AW, manuscript in preparation). This result, and additional data showing that the time course of MAP kinase activation and inactivation in response to growth factor treatment are similar in 23A2 and Ras9 cells (data not shown), demonstrates that the increased MAP kinase activity in Ras9 cells results directly from constitutive signaling by oncogenic Ras.
Eect of a synthetic inhibitor of the MAP kinase pathway (PD 098059) on the level of MAP kinase activity in 23A2 and Ras9 cells PD 098059 selectively blocks the activation of MEK1, the immediate upstream activator of MAP kinase (Alessi et al., 1995) . This inhibitor reduces the basal MAP kinase activity in Ras-transformed Balb3T3 and rat kidney cells and inhibits MAP kinase activation by PDGF in Swiss 3T3 cells and by NGF in PC12 cells . 23A2 and Ras9 cells were treated with PD 098059 for 24 h prior to lysis and the determination of MAP kinase activity. Again, MAP kinase activity from Ras9 cells in growth medium was modestly elevated compared to that from control 23A2 cells. Activity in each extract was reduced by roughly 50% after 24 h in dierentiation medium ( Figure 2a ). After a 24 h incubation in dierentiation medium with PD 098059, the MAP kinase activity from Ras9 cells decreased to a level even lower than the MAP kinase activity from 23A2 cells in differentiation medium ( Figure 2a ). PD 098059 also blocked the activation of MAP kinase by serum or puri®ed growth factors ( Figure 2b ). These PD 098059 mediated blockades to MAP kinase stimulation after 24 h were equal to those obtained when cells were incubated with PD 098059 for 30 min or 48 h (data not shown) and are consistent with previous reports on the stability and ecacy of PD 098059 .
Eects of PD 098059 on the proliferation and morphology of 23A2 and Ras9 cells
To assess the proliferative capacities of 23A2 and Ras9 cells maintained for 24 h in either growth medium or dierentiation medium, the amount of newly synthesized DNA in the cultures was measured by pulse labeling cells with [ kidney cells . Incubation of Ras9 cells with PD 098059 similarly had a dramatic eect on their transformed morphology causing them to lose their refractile appearance,¯atten out and closely resemble the morphology of 23A2 myoblasts in dierentiation medium (Figure 4) . Similar results were obtained when either thymidine incorporation or morphology was monitored at 48 h (data not shown).
Inhibition of the MAP kinase pathway does not reverse the dierentiation-defective phenotype of Ras9 cells or abrogate the establishment of the dierentiationdefective phenotype by oncogenic Ha-Ras PD 098059 also has been used to demonstrate a requirement for the MAP kinase pathway in NGFinduced neuronal dierentiation of PC12 cells . Since PD 098059 reduces the MAP kinase activity in Ras9 cells to a level which is comparable to that observed in 23A2 cells in dierentiation medium over a length of time sucient to allow dierentiation, PD 098059 could be a useful reagent to examine the contribution of elevated MAP kinase activity to the dierentiation-defective phenotype of Ras9 cells if it does not interfere with the dierentiation of 23A2 myoblasts. Undierentiated 23A2 myoblasts in growth medium do not express the muscle-speci®c myosin heavy chain protein (MHC) ( Figure 5 ). Treating 23A2 myoblasts with dierentiation medium for 24 or 48 h induces dierentiation as monitored by the expression of MHC ( Figure 5 ) and the fusion into multinucleate myo®bers (data not shown). 23A2 myoblasts treated with dierentiation medium containing PD 098059 similarly expressed MHC after 24 or 48 h ( Figure 5 ) and fused into myo®bers (data not shown). Ras9 cells, which are dierentiation-defective, did not express MHC in growth medium and did not express MHC or fuse into myo®bers after 24 or 48 h in dierentiation medium ( Figure 5 and data not shown). Ras9 cells treated with dierentiation medium containing PD 098059 did not fuse into myo®bers (data not shown) and did not express MHC as detected either by Western blot analysis (Figure 5 ) or by immunostaining of ®xed cells (data not shown). These results indicate that MAP kinase activity is not required by oncogenic Ras to maintain the dierentiation-defective phenotype.
It is possible that the inability to regain a myogenic response in the Ras9 cells by treating with PD 098059 to eliminate their increased MAP kinase activity is due to a secondary eect of the long-term culturing of this cell line. Therefore, to determine if activation of MAP kinase is required for oncogenic Ras to establish a dierentiation-defective phenotype, transient transfection assays were performed. Since the eciency of transient transfections is typically around 10%, transiently transfecting 23A2 myoblasts with an expression vector for oncogenic Ras would result in a dierentiation-defective phenotype for roughly 10% of the cells. Determining the signi®cance of MAPK signaling by measuring the abrogation by PD 098059 of this minimal inhibition would not be practical. For this reason, these experiments were performed using C3H10T1/2 ®broblasts and expression vectors for the myogenic regulatory factor MyoD (pEMscribeMyoD) and for activated Ha-Ras (pDCRG12V). Previous studies have shown that ectopic MyoD expression can convert C3H10T1/2 cells to skeletal muscle precursors and that co-expression of an oncogenic ras gene in this assay inhibits MyoD activity by greater than 90% (Kong et al., 1995) . C3H10T1/2 cells were transfected with DNA precipitates containing either pEMscribeMyoD or pEMscribeMyoD and pDCRG12V. After 48 h in dierentiation medium, with or without PD 098059, cell lysates were prepared and analysed by immunoblot for the expression of MHC (Figure 6a ). In addition, parallel cultures were ®xed and immunostained for MHC to visualize the extent of myo®ber formation in each experimental group (Figure 6b ). C3H10T1/2 cells transfected with MyoD expressed MHC and displayed extensive myo®ber networks regardless of whether they had been treated with PD 098059 or not. On the other hand, C3H10T1/2 cells co-transfected with MyoD and oncogenic Ha-Ras were unable to dierentiate and exposure to PD 098059 did not reverse their nonmyogenic phenotype. Quantifying the number of MHC positive cells in the Ras/MyoD co-transfected cultures treated with or without PD 098059 revealed that the eciency of ®ber formation in the presence of Ras was less than 2% of control cultures transfected with MyoD alone. Since treatment with PD 098059 eliminates the increase in MAP kinase activity observed in C3H10T1/2 cells transiently transfected with oncogenic Ras (MBR and EJT in preparation), these results demonstrate that activation of MAP kinase is not required by oncogenic Ras to establish a dierentiation-defective phenotype.
Discussion
The eector domain or switch 1 region of Ras is critical for the associtaion of Ras with Raf-1 and BRaf (Moodie et al., 1993 , Neuro®bromin (DiBattiste et al., 1993) , PI3 kinase (RodriguezViciana et al., 1994) , Ral GDS (Hofer et al., 1994; Kikuchi et al., 1994; Spaargaren and Bischo, 1994) . Rin1 (Han and Colicelli, 1995) and AF6 (Kuriyama et al., 1996) . Mutations in this region render Ras biologically inactive (Lowy and Willumsen, 1993) . Transformation and inhibition of myoblast differentiation by oncogenic Ras are both abrogated by coexpression of Rap1A (Bokoch, 1993; Kong et al., 1995) . Rap1A has an eector domain identical to Ras and it has been proposed that Rap1A directly competes with Ras for downstream eectors (Bokoch, 1993) . The downstream eector(s) required by oncogenic Ras to render skeletal myoblasts transformed and differentiation-defective, however, is not known.
The signi®cance of signaling from activated Ras or oncogenic Ras to Raf-1 or B-Raf and from Raf kinases to MEK1 and MAP kinases is well-established Moodie et al., 1994; Jaiswal et al., 1994; Jelinek et al., 1994; Reuter et al., 1995) . PD 098059 is a selective inhibitor of MEK1 activation (Alessi et al., 1995) and has been used to demonstrate the requirement for MAP kinase activation in the PDGF-induced DNA synthesis of Swiss3T3 ®broblasts, the growth of Ras-transformed Balb3T3 ®broblasts and rat kidney cells , and the NGF-induced dierentiation of PC12 cells . In this study, we used PD 098059 to determine if the same or distinct signaling pathways are utilized by oncogenic Ras to render skeletal myoblasts transformed and dierentiation-defective. We have shown that 23A2 myoblasts stably expressing an oncogenic Ha-ras gene possess modestly increased MAP kinase activity compared to control 23A2 myoblasts. This increase in MAP kinase activity was observed regardless of whether cultures were maintained in either growth or dierentiation medium. This modest increase in MAP kinase activity in Ras9 cells is not surprising since the expression of oncogenic Ha-ras is controlled by its native promoter and ectopic Ha-Ras protein levels are similar to that of endogenous K-and N-Ras in the parental 23A2 myoblasts (data not shown). This level of oncogenic Ha-Ras is, nonetheless, sucient to permit DNA synthesis after serum withdrawal, to induce morphological transformation, and to inhibit myoblast differentiation. If this increased MAP kinase activity is responsible for the oncogenic Ras-induced phenotype in 23A2 myoblasts, then decreasing MAP kinase activity in Ras9 cells to at least the level of MAP kinase activity in 23A2 cells should revert the phenotype of Ras9 cells to that of 23A2 cells.
Ras9 cells cultured in either growth or dierentiation medium with PD 098059 possessed less MAP kinase activity than 23A2 myoblasts cultured in dierentiation medium. Incubation with PD 098059 reverted the morphology of Ras9 cells and abrogated their serumindependent proliferation. Treatment of Ras9 cells with dierentiation medium containing PD 098059 did not, however, allow the Ras9 cells to express myosin heavy chain. Although cell cycle exit is a necessary prerequisite for skeletal muscle dierentiation (Andres and Walsh, 1996) , the ability of oncogenic Ras to inhibit myogenesis is proliferation independent Payne et al., 1987; Gossett et al., 1988) . It is not surprising, therefore, that PD 098059-induced growth arrest in Ras9 cells did not abrogate their dierentiation-defective phenotype. However, the failure of the PD 098059-mediated elimination of elevated MAP kinase activity to revert the dierentiationdefective phenotype of oncogenic Ras-expressing myoblasts is only the second (White et al., 1995; Joneson et al., 1996) oncogenic Ras-induced biological endpoint which is MAP kinase independent. We have shown previously that protein kinase C (PKC) is required only to establish, and not to maintain, the oncogenic Ras-dependent dierentiation-defective phenotype (Vaidya et al, 1991) . To eliminate the possibility that a similar requirement exists for increased MAP kinase activity, we have shown that PD 098059 also does not prevent the establishment of the differentiation-defective phenotype when oncogenic Ha-ras and MyoD are transiently cotransfected into C3H10T1/2 ®broblasts.
In this study, we have demonstrated that, while increased MAP kinase activity is required for the transformation of 23A2 myoblasts by oncogenic Ras, elevated MAP kinase activity is not required by oncogenic Ras to establish or to maintain a block of myoblast dierentiation. This does not rule out the possibility that constitutive signaling by MAP kinase could inhibit dierentiation, but clearly demonstrates that other pathways activated by oncogenic Ras are sucient to inhibit myoblast dierentiation. Ras signaling leads to the activation of multiple pathways, many of which could be sucient to inhibit myoblast dierentiation by themselves. A systematic assessment of each signaling pathway activated by Ras is required to determine which signaling events are sucient and which signaling events are necessary for inhibition of myoblast dierentiation.
Materials and methods

Reagents
The anti-MAP kinase antibody (TR10) was provided by Dr Michael Weber. PD 098059 was provided by Dr Alan Saltiel (Parke-Davis).
Cells and cell culture
The growth and dierentiation properties of 23A2 myoblasts and the 23A2 derivative expressing the human Ha-ras oncogene (Ras9 cells) have been reported previously (Konieczny et al., 1989) . Undierentiated, proliferating 23A2 and Ras9 cells were maintained in growth medium (BME supplemented with 10% FBS and 1% P/S) at low density on gelatin coated dishes. Dierentiation was induced by treating the cells with dierentiation medium (BME, 1% P/S). C3H210T1/2 cells were cultured on non-gelatinized dishes under the same conditions as the C3H10T1/2-derived 23A2 myoblast cell line. PD 098059 was dissolved in DMSO to give a ®nal concentration of 37 mM and stored at 7808C. PD 098059 was added to the culture medium to a ®nal concentration of 100 mM. DMSO alone (50.15% v/v) was added to control cultures.
MAP kinase activity assay
Cell extracts were prepared in p21 buer (20 mM MOPS pH 7.4, 4 mM magnesium chloride, 200 mM sucrose, 0.1 mM EDTA) supplemented with 1% CHAPS, protease and phosphatase inhibitors. TR10 antibody precoupled to protein A sepharose was added to extracts followed by rotation for 1 h at 48C. After sedimentation, pellets were washed three times with Tris-buered saline (TBS)/0.1% NP40 and once with p21 buer and then incubated for 20 min at 378C with 25 mM myelin basic protein (MBP), 10 mM [g-32 P]ATP (10 mCi, 44500 Ci/mmol) and 10 mM phosphatase inhibitors in a total volume of 50 ml (Moodie et al., 1993) . Assays were performed within the linear range of 32 P incorporation and were terminated by the addition of 26Laemmli buer. Reaction products were separated by discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS ± PAGE: 15%). The gel was dried and phosphorylated bands visualized and quantitated by Phosphorimager analysis.
Thymidine incorporation
Equal numbers of 23A2 and Ras9 cells were plated and the next day either refed growth medium (GM) or switched to dierentiation medium (DM) with or without 100 mM PD 098059 for 24 h. During the ®nal 4 h, cultures were supplemented with 1 mCi/ml of [methyl-3 H]thymidine. Cultures were washed with TBS and ®xed by two incubations with 10% trichloroacetic acid. Acid insoluble material was dissolved by the addition of 0.2 N sodium hydroxide supplemented with salmon sperm DNA carrier (40 mg/ml) and quantitated by liquid scintillation counting.
Immunoblot analysis
Cell extracts were equalized for total cell protein, denatured by addition of Laemmli buer, resolved by SDS ± PAGE (8%) and electrophoretically transferred to Immobilon P. The Immobilon P was blocked for 1 h at room temperature in TBS/0.1% NP40 with 1% calf serum and 5% dry milk. After washing with TBS/0.1% NP40, the Immobilon P was incubated for 1 h with MF20, a mouse monoclonal antibody speci®c for skeletal muscle myosin heavy chain. After washing 56 with TBS/0.1% NP40 (10 min each), the immobilon P was incubated for 1 h with a rabbit anti-mouse secondary antibody (1 : 1000), washed as before and incubated for another hour with 125 I-labeled goat anti-rabbit (5 mCi) antibody (Amersham). After washing, [
125 I] was visualized and quantitated by Phosphorimager analysis. Alternatively, after incubation with MF20 antibody and washing, the blot was incubated for 45 min with goat anti-mouse IgG conjugated to horseradish peroxidase (1 : 3000, Santa Cruz). After washing, immunoreactive bands were detected using standard enhanced chemiluminescence techniques.
Transient transfections
Transient DNA transfections were performed using the calcium phosphate-mediated transfer technique (Kong et al., 1995) . Brie¯y, C3H10T1/2 cells were plated at 4610 5 cells/gelatin-coated 60 mm dish. The following day, DNA calcium phosphate precipitates consisting of 2.5 mg pEMscribe MyoD (Davis et al., 1987) and 5.0 mg pDCR vector or pDCRHa-ras G12V (White et al., 1995) were added to the dishes. Four hours later, the cells were subjected to osmotic shock for 90 s in serum-free BME medium containing 20% glycerol and then switched to growth medium. After 20 h, the cells were fed differentiation medium containing 100 mM PD 098059 or an equivalent volume of DMSO. The cells were incubated for an additional 48 h before cells were either lysed for immunoblot analysis or ®xed for immunohistochemistry.
Immunohistochemistry
Cells were rinsed twice with cold 16phosphate-buered saline (PBS) and ®xed for 1 min with a solution of 70% ethanol : formalin : acetic acid (20 : 2 : 1). Fixed cells were permeabilized with TBS/0.1% NP40 and blocked by incubation with 2% horse serum in PBS. This was followed by incubation with the MF20 antibody, washing, incubation with a biotinylated goat anti-mouse IgG secondary antibody (1 : 300, Vector Laboratories), washing, and incubation with horseradish peroxidase streptavidin (1 : 250, Vector Laboratories). Immunoreactivity was visualized using a solution of 3,3'-diaminobenzidine (1 mg/ml), 30% H 2 O 2 (1 ml/ml) and NiCl 2 (5 mg/ml) in PBS.
